Cargando…

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date

The c-MET proto-oncogene (MET) plays an important role in lung oncogenesis, affecting cancer-cell survival, growth and invasiveness. The MET receptor in non-small–cell lung cancer (NSCLC) is a potential therapeutic target. The development of high-output next-generation sequencing techniques has enab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bylicki, Olivier, Paleiron, Nicolas, Assié, Jean-Baptiste, Chouaïd, Christos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306460/ https://www.ncbi.nlm.nih.gov/pubmed/32606781 http://dx.doi.org/10.2147/OTT.S219959

Ejemplares similares

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
por: Bylicki, Olivier, et al.
Publicado: (2018)

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
por: Gendarme, Sébastien, et al.
Publicado: (2022)

Targeted therapy for localized non-small-cell lung cancer: a review
por: Paleiron, Nicolas, et al.
Publicado: (2016)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care
por: Bylicki, Olivier, et al.
Publicado: (2019)

Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
por: Assié, Jean-Baptiste, et al.
Publicado: (2023)

Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis
por: Gendarme, Sébastien, et al.
Publicado: (2021)

Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
por: Assié, Jean-Baptiste, et al.
Publicado: (2020)

Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy
por: Grambow-Velilla, Julia, et al.
Publicado: (2023)

Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab
por: Chouaïd, Christos, et al.
Publicado: (2022)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

Risk factors for early mortality of lung cancer patients in France: A nationwide analysis
por: Goussault, Hélène, et al.
Publicado: (2022)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

MET in glioma: signaling pathways and targeted therapies
por: Cheng, Fangling, et al.
Publicado: (2019)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
por: Chouaid, Christos, et al.
Publicado: (2018)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
por: Chouaïd, Christos, et al.
Publicado: (2020)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer
por: Fong, Jason T., et al.
Publicado: (2013)

LUCSO-1—French pilot study of LUng Cancer Screening with low-dose computed tomography in a smokers population exposed to Occupational lung carcinogens: study protocol
por: Delva, Fleur, et al.
Publicado: (2019)

MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies
por: Rivas, Solange, et al.
Publicado: (2022)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

Nurses confronting the coronavirus: Challenges met and lessons learned to date
por: Ulrich, Connie M., et al.
Publicado: (2020)

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2021)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
por: Chouaïd, Christos, et al.
Publicado: (2014)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
por: Taniguchi, Hirokazu, et al.
Publicado: (2017)

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
por: Ma, P C, et al.
Publicado: (2007)

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
por: Seban, Romain-David, et al.
Publicado: (2020)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway
por: Wang, Anqi, et al.
Publicado: (2022)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
por: Spagnolo, Calogera Claudia, et al.
Publicado: (2023)

Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient
por: Roseau, Jean Baptiste, et al.
Publicado: (2016)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

The demography of swiping right. An overview of couples who met through dating apps in Switzerland
por: Potarca, Gina
Publicado: (2020)

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients
por: Gounant, Valérie, et al.
Publicado: (2021)

The role of HGF/c-MET signaling pathway in lymphoma
por: Lam, Bao Quoc, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d23bngc2e2mv4gkr9ua7ru98u9